Course1

2025 BCLT Privacy Law Forum: Life Sciences

$280.00
  • Instructor(s):  BCLT

Through the 2025 BCLT Privacy Law Forum: Life Sciences virtual conference, BCLT invites you to explore cutting-edge issues crucial for lawyers, in-house counsel, government regulators, and academics working in the privacy and cybersecurity spaces. Throughout the summer and fall, BCLT will launch the programs you need to watch. Explore updates on health-focused privacy laws, AI's impact on privacy issues, wearables and age-related privacy protections, and international data transfers. This is a must-view program for anyone who is encountering privacy issues in the context of the life sciences ecosystem.

  • Bundle
  • 3
    Programs
  • 4/1/27
    Avail. to
  • DETAILS
Course1

2025 Privacy Law Forum: Life Sciences - (Session 1) International Data Transfers

$115.00
  • Instructor(s):  BCLT

Session 1: International Data TransfersBCLT Life Sciences Law & Policy CenterTuesday, June 24, 2025 | 1:00 p.m. | B-CLE Program Information | Resources Join Lokke Moerel and Kaylee Cox Bankston from Morrison Foerster to learn what you need to know about international data transfers.  Lokke and Kaylee will explore the US and EU international data transfer regimes in detail, and how lawyers and clients can best navigate these complex regimes in these changing geo-policital times. The EU data transfer regime has started out as a protection of fundamental privacy rights of individuals but is now becoming a tool in the EU’s ambition for digital sovereignty. Lokke will discuss why the EU’s digital sovereignty is under threat, what the chances are the EU-US Data Privacy Framework will be invalidated, how EU policy measures will facilitate open data spaces for AI innovation while ensuring EU sovereignty by introducing further transfer regimes (basically amounting to data localization requirements) and how Big Tech is responding with EU cloud boundaries. The session will end with recommendations for how to navigate this complex legal landscape. Don’t miss this excellent program! Speakers: Kaylee Cox Bankston, Morrison Foerster Lokke Moerel, Morrison Foerster   Program Series: Through the 2025 BCLT Privacy Law Forum: Life Sciences virtual conference, BCLT invites you to explore cutting-edge issues crucial for lawyers, in-house counsel, government regulators, and academics working in the privacy and cybersecurity spaces. Throughout the summer and fall, BCLT will launch the programs you need to watch. Explore updates on health-focused privacy laws, AI's impact on privacy issues, wearables and age-related privacy protections, and international data transfers. This is a must-view program for anyone who is encountering privacy issues in the context of the life sciences ecosystem. Presented by  

  • On-Demand
    Format
  • 50
    Min.
  • 4/1/27
    Avail. to
  • DETAILS
Course1

2025 Privacy Law Forum: Life Sciences - (Session 2) Matrices of Privacy: Where Are Wearables Taking You?

$50.00
  • Instructor(s):  BCLT

Session 2: Matrices of Privacy: Where Are Wearables Taking You?2025 Privacy Law Forum: Life SciencesBCLT Life Sciences Law & Policy CenterWednesday, September 10, 2025 | 1:00 p.m. | B-CLE 0.50 General CLE & CPE Credit Available Series Information | Resources | Speaker Bios & Contact Info As wearable technologies become deeply embedded in our daily lives—from smartwatches and fitness trackers to clinical-grade health monitors—they are collecting more sensitive personal data than ever before. But what does that mean for your privacy? Join us as legal and bioethics expert Rachel Zuraw, from UC Berkeley School of Law, explores the complex and fast-evolving world of wearables, data collection, and digital privacy. You’ll unpack the regulatory landscape, consider what health data is (and isn’t) protected, and discuss how age, vulnerability, and emerging technologies are reshaping the future of health privacy. Whether you're in healthcare, tech, law, or policy, this conversation will equip you to think more critically about the digital devices we wear—and the hidden data trails we leave behind. In this session, you will learn: What privacy really means in the age of wearables—and why it’s not so simple How different privacy regulations apply to wearable technologies What health data is protected—and what isn’t How to identify privacy risks tied to aging and long-term care tech Who benefits from wearable data and who may be left exposed Speaker(s):   Rachel Zuraw, UC Berkeley School of Law   Program Series: Through the 2025 BCLT Privacy Law Forum: Life Sciences virtual conference, BCLT invites you to explore cutting-edge issues crucial for lawyers, in-house counsel, government regulators, and academics working in the privacy and cybersecurity spaces. Throughout the summer and fall, BCLT will launch the programs you need to watch. Explore updates on health-focused privacy laws, AI's impact on privacy issues, wearables and age-related privacy protections, and international data transfers. This is a must-view program for anyone who is encountering privacy issues in the context of the life sciences ecosystem. Presented by  

  • On-Demand
    Format
  • 30
    Min.
  • 4/1/27
    Avail. to
  • DETAILS
Course1

2025 Privacy Law Forum: Life Sciences - (Session 3) AI, Privacy, and Life Sciences

$115.00
  • Instructor(s):  BCLT

Session 3: AI, Privacy, and Life Sciences2025 Privacy Law Forum: Life SciencesBCLT Life Sciences Law & Policy CenterWednesday, September 17, 2025 | 1:00 p.m. | B-CLE 0.75 General CLE & CPE Credit Available Series Information | Resources | Speaker Bios & Contact Info AI is revolutionizing life sciences—from drug discovery to diagnostics—but it’s also raising urgent questions about data privacy, legal risk, and regulatory compliance. Join legal experts Thora Johnson and Shannon Yavorsky from Orrick for an engaging and practical session on how companies can responsibly and lawfully innovate at the intersection of AI, health data, and genomics. We’ll explore real-world examples, including multi-omics research, global data sharing, and new rules like the DOJ’s Bulk Data Rule and the EU AI Act. Whether you're working with patient data, developing AI models, or leading compliance, this session will provide the clarity and foresight you need. Perfect for life sciences innovators, legal, compliance, and digital health professionals seeking practical, future-ready insights in a rapidly evolving landscape. You’ll learn how to: Understand how AI is transforming the life sciences industry Navigate U.S. and global privacy law Understand the legal and ethical risks of using omics data and AI models Comply with the DOJ Bulk Data Rule and EU AI Act Assess real-world challenges Speaker(s): Thora Johnson, Orrick, Herrington & Sutcliffe Shannon Yavorsky, Orrick, Herrington & Sutcliffe   Program Series: Through the 2025 BCLT Privacy Law Forum: Life Sciences virtual conference, BCLT invites you to explore cutting-edge issues crucial for lawyers, in-house counsel, government regulators, and academics working in the privacy and cybersecurity spaces. Throughout the summer and fall, BCLT will launch the programs you need to watch. Explore updates on health-focused privacy laws, AI's impact on privacy issues, wearables and age-related privacy protections, and international data transfers. This is a must-view program for anyone who is encountering privacy issues in the context of the life sciences ecosystem. Presented by  

  • On-Demand
    Format
  • 30
    Min.
  • 4/1/27
    Avail. to
  • DETAILS
Course1

2nd BCLT Advanced Life Sciences Institute

$970.00
  • Instructor(s):  BCLT

Rapid advancement in life sciences technologies has made keeping up with the legal implications more important than ever. Join us for the 2nd BCLT Advanced Life Sciences Institute, where you will learn from the experts about cutting-edge issues impacting your life sciences practice. Our programming will share key insights and best practices related to the rapid rise of AI in the life sciences and new trends for licensing, deals, and life sciences funding models. We will also have experts reviewing key developments in the law (Section 112, obviousness-type double patenting), anti-counterfeiting and patient safety, and the ever-complex interplay of regulatory and IP exclusivities. Finally, don’t miss our in-depth discussions on future pandemic preparedness and use of trade secrets v. patents for portfolio protection!

  • Bundle
  • 11
    Programs
  • 6/6/27
    Avail. to
  • DETAILS
Course1

3rd BCLT Advanced Life Sciences Institute Series

$575.00
  • Instructor(s):  BCLT & Gibson Dunn, BCLT

Life sciences technologies continue to develop and evolve, regulatory agencies undergo rapid change, and the practice of life sciences law moves at an ever-increasing pace. To make sure you are up to date, the 3rd BCLT Advanced Life Sciences Institute series is mandatory viewing on key cutting-edge issues impacting your practice. Catch up on our three-part exploration of royalty financing for life sciences companies, and check out two new program launches: (1) updates on the application of safe harbor provisions and FDA laboratory test regulation, and (2) key developments in the law related to patent disclosure.

  • Bundle
  • 5
    Programs
  • 9/16/27
    Avail. to
  • DETAILS
Course1

After Schedule I: Federal Psychedelic Rescheduling and the Impact on State Law

FREE
  • Instructor(s):  BCLT

Monday, November 17 | 1:00 - 2:00 pm (PT) | ZoomBCLT Life Sciences Law & Policy Center 1.00 General CLE Credit Available Program Info | Resources Psychedelics have long been legally inaccessible. That might change soon. Join us as we explore the complex legal and regulatory pathway for psychedelic drug rescheduling. As promising clinical trial data for substances like psilocybin and MDMA emerges, a critical question remains: how should these compounds move from Schedule I of the Controlled Substances Act to become accessible medical treatments? This discussion aims to demystify the rescheduling process and the central role of the FDA in that evaluation, featuring experts from the Multidisciplinary Association for Psychedelic Studies (MAPS), Porta Sophia, and New Approach PAC. We will also analyze the downstream consequences, including how state-level "trigger laws" might automatically — or fail to automatically — conform to a new federal schedule, creating a complex patchwork of state and federal legality. SPEAKERS Vincent JoralemonDirector, Life Sciences Law & Policy Center, BCLT, UC Berkeley Law Ismail L. AliCo-Executive Director, MAPS Graham PechenikFounder, Calyx Law Shahin ShamsData and Patent Analyst, Porta Sophia Tamar ToddLecturer, UC Berkeley Law

  • On-Demand
    Format
  • 60
    Min.
  • 6/1/28
    Avail. to
  • DETAILS
Course1

AI as an Inventing Tool: AI’s challenges to Patent law – Inventorship (Panel 2)

$115.00
  • Instructor(s):  BCLT

AI as an Inventing Tool—Its Implicatioins for Patent Law and PolicyRecorded November 15, 2023 Event Information | Agenda | Resources   Participate in Professor Colleen Chien's Study!   Speakers Prof. Dennis CrouchUniversity of Missouri School of Law Yuan Hao, PhDBCLT, Berkeley Law Nalini MummalaneniUSPTO Moderator Prof. Robert MergesBCLT, Berkeley Law

  • On-Demand
    Format
  • 59
    Min.
  • 6/3/26
    Avail. to
  • DETAILS
Course1

Assessing Patent Protections Afforded Under the Safe Harbor Provision

$115.00
  • Instructor(s):  BCLT

Assessing Patent Protections Afforded Under the Safe Harbor Provision3rd BCLT Advanced Life Sciences Institute SeriesBCLT Life Sciences Law & Policy CenterTuesday, August 19, 2025 | 1:00 p.m. | B-CLE 0.75 General CLE Credit Available Program Info | Resources | Speaker Bios & Contact Info Join Kirkland partners Tasha Gerasimow and Joseph Loy, along with Novartis Senior IP Counsel Jessica Lam, to explore patent protections and recent regulatory developments related to the safe harbor of the Hatch-Waxman Act.  The safe harbor provision exempts certain uses of patented inventions related to FDA-regulated products from infringement.  Our speakers explore the breadth of applicability of the safe harbor provision to numerous products (drugs, biologics, and medical devices) and activities.  The program also covers implications for third-party entities (API suppliers, research tool providers) and provides key practice tips to ensure the safe harbor is available.  Finally, the program examines recent regulatory developments for laboratory-developed test services likely to be impacted by the safe harbor provision.  Don't miss this important program! Ideal for IP counsel, regulatory teams, and innovators in biotech, pharma, and diagnostics. You’ll learn how to: Apply the Safe Harbor provision to R&D and regulatory activity Determine whether research tools or third-party suppliers are protected Avoid pitfalls in stockpiling and basic research practices Understand the latest court rulings and regulatory developments Use best practices to strengthen your legal position   Speakers: Tasha Gerasimow, Kirkland & Ellis Jessica Lam, Novartis Joseph Loy, Kirkland & Ellis 3rd BCLT Advanced Life Sciences Institute Series Series Info | Resources | 3rd ALSI Subseries Program Series: Life sciences technologies continue to develop and evolve, regulatory agencies undergo rapid change, and the practice of life sciences law moves at an ever-increasing pace. To make sure you are up to date, the 3rd BCLT Advanced Life Sciences Institute series is mandatory viewing on key cutting-edge issues impacting your practice. Catch up on our three-part exploration of royalty financing for life sciences companies, and check out two new program launches: (1) updates on the application of safe harbor provisions and FDA laboratory test regulation, and (2) key developments in the law related to patent disclosure.  The Advanced Life Sciences Institute will be launched virtually through B-CLE.  You do not want to miss this special event!   Registration is free and available to all, and CLE will be offered.   Presented by  

  • On-Demand
    Format
  • 45
    Min.
  • 2/1/27
    Avail. to
  • DETAILS
Course1

Examining Written Description

$115.00
  • Instructor(s):  BCLT

Examining Written Description3rd BCLT Advanced Life Sciences Institute SeriesBCLT Life Sciences Law & Policy CenterTuesday, August 26, 2025 | 1:00 p.m. | B-CLE 1.00 General CLE Credit Available Program Info | Resources | Speaker Bios & Contact Info The written description requirement under 35 U.S.C. § 112 continues to shape the outcome of high-stakes patent litigation. In this engaging and practical session, Kiley White of Tensegrity Law Group unpacks the latest Federal Circuit and district court decisions, highlighting how state of the art knowledge, expert testimony, and claim drafting strategies can make—or break—your case. Whether you represent patentees or challengers, you’ll leave with concrete tools to strengthen your litigation and prosecution approaches. You’ll learn how to:   Navigate broad and genus claim challenges Use expert testimony effectively without overstepping Draft specifications that withstand § 112 scrutiny Speakers:Kiley White, Tensegrity Law Group 3rd BCLT Advanced Life Sciences Institute Series Series Info | Resources | 3rd ALSI Subseries Program Series: Life sciences technologies continue to develop and evolve, regulatory agencies undergo rapid change, and the practice of life sciences law moves at an ever-increasing pace. To make sure you are up to date, the 3rd BCLT Advanced Life Sciences Institute series is mandatory viewing on key cutting-edge issues impacting your practice. Catch up on our three-part exploration of royalty financing for life sciences companies, and check out two new program launches: (1) updates on the application of safe harbor provisions and FDA laboratory test regulation, and (2) key developments in the law related to patent disclosure.  The Advanced Life Sciences Institute will be launched virtually through B-CLE.  You do not want to miss this special event!   Registration is free and available to all, and CLE will be offered.   Presented by  

  • On-Demand
    Format
  • 53
    Min.
  • 3/1/27
    Avail. to
  • DETAILS
Course1

Hot Topics in Biometrics and Genetics

$115.00
  • Instructor(s):  BCLT & Morgan Lewis

Program Occurred on 2/20/2025 Event Information | Resources Extreme liability—that is the image that biometric data conjures up for any product lawyer in the space. But what does the current reality look like? Should you really be avoiding Illinois with your biometric-based products? What about genetic data? What are the risks? This session looks at the current risks and then offers practical guidance for evaluating and managing those risks. Have a topical question? Reach out to our speaker(s) via the hyperlinks below! Speaker(s): Beth Herrington, Morgan Lewis Warren Rissier, Morgan Lewis

  • On-Demand
    Format
  • 49
    Min.
  • 7/1/26
    Avail. to
  • DETAILS
Course1

Royalty Finance, the UCC and Issues of Recharacterization

$345.00
  • Instructor(s):  BCLT & Gibson Dunn

Presented by BCLT Life Sciences Law & Policy Center? In the context of chaotic capital markets over the last five years (the XBI has dropped 48% from January 2021 to March 2025 and an 80% drop in Biotech IPO issuances from 2021 to the end of 2024), where biotech companies must continue to raise capital, synthetic royalty finance transactions have emerged as an attractive financing structure that is nondilutive, uncorrelated with the markets, and a relatively low cost of capital.  The market saw steady growth in the aggregate deal value of synthetic royalty finance transactions over the last five years, with an average annual growth rate of 33% over the period.  With the increase in the number of synthetic royalty finance transactions structured as true sales, questions have arisen throughout the industry as to what exactly is being sold and what are the risks and advantages of acquiring a synthetic royalty. In this three-part virtual series, BCLT & Gibson, Dunn & Crutcher have partnered issues originally raised in a Law 360 article written by Gibson Dunn attorneys, Todd Trattner and Ryan Murr, entitled How Biotech Cos. Can Utilize Synthetic Royalty Financing. Gibson Dunn attorneys explore, in depth, royalty finance, looking at synthetic royalties, the treatment of synthetics under the UCC, and the risks of a sale of a synthetic royalty being recharacterized as a loan in bankruptcy.  The aim of this virtual speaker series is to educate biotechnology stake holders (investors, entrepreneurs, companies, and their attorneys) on best practices for monetizing and investing in a synthetic royalty so that they may embark on such transactions with greater certainty. For anyone with an interest in how modern biotechnology companies raise capital, this series will help you optimize your rights and reduce your risks. Don’t miss it!

  • Bundle
  • 3
    Programs
  • 6/17/27
    Avail. to
  • DETAILS
Course1

Royalty Finance, the UCC and Issues of Recharacterization: (Panel 1) Royalty Finance: Structures, Trends and Synthetics

$150.00
  • Instructor(s):  BCLT & Gibson Dunn

Program occurred on May 6, 2025 Program Information | Resources Presented by BCLT Life Sciences Law & Policy Center This panel will provide an overview of the different types and structures of royalty finance transactions and a summary of the number of deals and economic trends over the last five years, and will conclude with an in-depth look at synthetic royalty financings, including drafting and true-sale considerations.   Have a topical question? Reach out to our speakers via the hyperlinks below or their Speaker Bios & Contact Info in the resources page! Speakers: Allison Schmitt, UC Berkeley Center for Law & Technology Todd Trattner, Gibson Dunn Ryan Murr, Gibson Dunn

  • On-Demand
    Format
  • 66
    Min.
  • 10/1/26
    Avail. to
  • DETAILS
Course1

Royalty Finance, the UCC and Issues of Recharacterization: (Panel 2) Synthetic Royalty Financings and the UCC

$115.00
  • Instructor(s):  BCLT & Gibson Dunn

Program Information | Resources Presented by BCLT Life Sciences Law & Policy Center This panel will provide an overview of security interests and UCC rules that are commonly implicated in royalty finance transactions and a high level overview of intercreditor considerations.   Have a topical question? Reach out to our speakers via the hyperlinks below or their Speaker Bios & Contact Info in the resources page! Speakers: Jin Hee Kim, Gibson Dunn Kali Jelen, Gibson Dunn Anthony Hajj, Gibson Dunn Moderator: Allison Schmitt, UC Berkeley Center for Law & Technology

  • On-Demand
    Format
  • 60
    Min.
  • 10/1/26
    Avail. to
  • DETAILS
Course1

Royalty Finance, the UCC and Issues of Recharacterization: (Panel 3) Synthetic Royalty Financings: Risks of Recharacterizing a True Sale

$115.00
  • Instructor(s):  BCLT & Gibson Dunn

Program Information | Resources Presented by BCLT Life Sciences Law & Policy Center This panel will address the factors that might cause a court to recharacterize purchases of royalties or synthetic royalties as a loan, rather than an outright transfer of ownership, or as a contract to convey future royalties as and when they arise, and the adverse consequences of such recharacterization if the seller/borrower becomes a debtor in a case under the Bankruptcy Code.   Have a topical question? Reach out to our speakers via the hyperlinks below or their Speaker Bios & Contact Info in the resources page! Speakers: Jeffrey C. Krause, Gibson Dunn Michael G. Farag, Gibson Dunn Moderator: Allison Schmitt, UC Berkeley Center for Law & Technology

  • On-Demand
    Format
  • 60
    Min.
  • 10/2/26
    Avail. to
  • DETAILS